LT2197481T - Rnr kompozicija, skirta nesmulkialąstelinio plaučių vėžio (nsclc) gydymui - Google Patents

Rnr kompozicija, skirta nesmulkialąstelinio plaučių vėžio (nsclc) gydymui

Info

Publication number
LT2197481T
LT2197481T LTEP08838033.2T LT08838033T LT2197481T LT 2197481 T LT2197481 T LT 2197481T LT 08838033 T LT08838033 T LT 08838033T LT 2197481 T LT2197481 T LT 2197481T
Authority
LT
Lithuania
Prior art keywords
nsclc
lung cancers
treating non
small lung
rna composition
Prior art date
Application number
LTEP08838033.2T
Other languages
English (en)
Inventor
Marijke Barner
Jochen Probst
Thomas Lander
Ingmar Hoerr
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of LT2197481T publication Critical patent/LT2197481T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEP08838033.2T 2007-10-09 2008-10-08 Rnr kompozicija, skirta nesmulkialąstelinio plaučių vėžio (nsclc) gydymui LT2197481T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2007/008770 WO2009046738A1 (en) 2007-10-09 2007-10-09 Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
PCT/EP2008/008503 WO2009046974A2 (en) 2007-10-09 2008-10-08 Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)

Publications (1)

Publication Number Publication Date
LT2197481T true LT2197481T (lt) 2018-06-25

Family

ID=39590300

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP08838033.2T LT2197481T (lt) 2007-10-09 2008-10-08 Rnr kompozicija, skirta nesmulkialąstelinio plaučių vėžio (nsclc) gydymui

Country Status (20)

Country Link
US (6) US20100291156A1 (lt)
EP (2) EP2197481B1 (lt)
JP (3) JP5139529B2 (lt)
CN (1) CN101820899B (lt)
AU (1) AU2008309930B2 (lt)
BR (1) BRPI0818318B8 (lt)
CA (1) CA2696768C (lt)
CY (1) CY1120168T1 (lt)
DK (1) DK2197481T3 (lt)
ES (1) ES2668926T3 (lt)
HR (1) HRP20180698T1 (lt)
HU (1) HUE037295T2 (lt)
LT (1) LT2197481T (lt)
MX (1) MX2010003766A (lt)
NO (1) NO2197481T3 (lt)
PL (1) PL2197481T3 (lt)
PT (1) PT2197481T (lt)
RU (1) RU2526510C2 (lt)
SI (1) SI2197481T1 (lt)
WO (2) WO2009046738A1 (lt)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2419143B8 (en) 2009-04-13 2018-06-27 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
CN101623503B (zh) * 2009-08-06 2011-07-27 中国人民解放军第三军医大学 生存素与路易斯寡糖的复合物及其制备方法和应用
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US9783821B2 (en) 2011-07-29 2017-10-10 Riken Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
US10316332B2 (en) 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
AU2013242404B2 (en) 2012-03-27 2018-08-30 CureVac SE Artificial nucleic acid molecules for improved protein or peptide expression
BR112014023898A2 (pt) 2012-03-27 2017-07-11 Curevac Gmbh moléculas de ácido nucleico artificiais compreendendo 5''utr top
KR102186497B1 (ko) 2012-03-27 2020-12-04 큐어백 아게 인공 핵산 분자
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
IN2014CH00393A (lt) * 2013-02-05 2015-04-03 Nitto Denko Corp
IN2014CH00391A (lt) 2013-02-05 2015-04-03 Nitto Denko Corp
KR20150119269A (ko) * 2013-02-12 2015-10-23 텍사스 테크 유니버시티 시스템 폐암의 진단 및 면역요법을 위한 조성물 및 방법
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
EP3292873B1 (en) 2013-02-22 2019-05-01 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
HUE046469T2 (hu) * 2013-08-21 2020-03-30 Curevac Ag Készítmény és vakcina tüdõrák kezelésére
EP3574916A1 (en) 2013-08-21 2019-12-04 CureVac AG Composition and vaccine for treating lung cancer
WO2015024664A1 (en) * 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating prostate cancer
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
CN105517569A (zh) 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗
CA2915730A1 (en) 2013-08-21 2015-02-26 Karl-Josef Kallen A combination rsv/influenza a vaccine
WO2015042325A1 (en) 2013-09-18 2015-03-26 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
BR112016014462A2 (pt) 2013-12-30 2017-10-24 Curevac Ag moléculas de ácido nucleico artificiais
WO2015101416A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Methods for rna analysis
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
JP6748579B2 (ja) 2014-06-10 2020-09-02 キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｎａ生成を強化する方法及び手段
EP3218508A4 (en) * 2014-11-10 2018-04-18 Modernatx, Inc. Multiparametric nucleic acid optimization
EP3041948B1 (en) 2014-11-10 2019-01-09 Modernatx, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
EP4241784A3 (en) 2014-12-12 2023-11-15 CureVac SE Artificial nucleic acid molecules for improved protein expression
WO2016165825A1 (en) 2015-04-13 2016-10-20 Curevac Ag Method for producing rna compositions
EP3283125B1 (en) 2015-04-17 2021-12-29 CureVac Real Estate GmbH Lyophilization of rna
MX2017013321A (es) 2015-04-22 2018-07-06 Curevac Ag Composicion que contiene arn para tratamiento de enfermedades tumorales.
WO2016172219A1 (en) * 2015-04-24 2016-10-27 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation
EP3289101B1 (en) 2015-04-30 2021-06-23 CureVac AG Immobilized poly(n)polymerase
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
US11559570B2 (en) 2015-05-15 2023-01-24 CureVac SE Prime-boost regimens involving administration of at least one mRNA construct
US10517827B2 (en) 2015-05-20 2019-12-31 Curevac Ag Dry powder composition comprising long-chain RNA
CN107530448A (zh) 2015-05-20 2018-01-02 库瑞瓦格股份公司 包含长链rna的干粉组合物
WO2016193226A1 (en) 2015-05-29 2016-12-08 Curevac Ag Method for adding cap structures to rna using immobilized enzymes
EP3744843A1 (en) 2015-05-29 2020-12-02 CureVac Real Estate GmbH A method for producing and purifying rna, comprising at least one step of tangential flow filtration
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017015463A2 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
EP3362461B1 (en) 2015-10-16 2022-03-16 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
HUE059127T2 (hu) 2015-10-22 2022-10-28 Modernatx Inc Légúti vírusok elleni vakcinák
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
AU2016375021B2 (en) 2015-12-22 2022-02-03 CureVac SE Method for producing RNA molecule compositions
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
SG11201806340YA (en) 2016-02-17 2018-09-27 Curevac Ag Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
EP3452493A1 (en) 2016-05-04 2019-03-13 CureVac AG Nucleic acid molecules and uses thereof
EP3458611B1 (en) * 2016-05-17 2023-11-08 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
EP3464619A1 (en) 2016-05-25 2019-04-10 CureVac AG Novel biomarkers
KR20190029576A (ko) 2016-06-09 2019-03-20 큐어백 아게 핵산 카고용 하이브리드 담체
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
CN109937253B (zh) 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
CN110582304A (zh) 2016-12-08 2019-12-17 库尔维科公司 用于治疗或预防肝脏疾病的rna
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
CN110430894A (zh) * 2017-02-01 2019-11-08 莫得纳特斯公司 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
PE20200735A1 (es) 2017-02-28 2020-07-23 Sanofi Sa Arn terapeutico
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
EP3601576A1 (en) 2017-03-24 2020-02-05 CureVac AG Nucleic acids encoding crispr-associated proteins and uses thereof
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
AU2018256877B2 (en) 2017-04-28 2022-06-02 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
CN111328287A (zh) 2017-07-04 2020-06-23 库瑞瓦格股份公司 新型核酸分子
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
AU2018328209A1 (en) 2017-09-05 2020-04-23 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2019077001A1 (en) 2017-10-19 2019-04-25 Curevac Ag NEW ARTIFICIAL NUCLEIC ACID MOLECULES
WO2019092153A1 (en) 2017-11-08 2019-05-16 Curevac Ag Rna sequence adaptation
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
CA3113212A1 (en) * 2018-09-28 2020-04-02 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
CN113166737A (zh) 2018-10-04 2021-07-23 新英格兰生物实验室公司 提高转录的rna的加帽效率的方法和组合物
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
RU2696872C1 (ru) * 2019-04-11 2019-08-07 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук" (Томский НИМЦ) Способ прогнозирования неблагоприятного исхода при немелкоклеточном раке легкого
CN112402596B (zh) * 2019-08-22 2023-12-08 上海细胞治疗集团有限公司 多肽组合物及疫苗
CN110456079B (zh) * 2019-09-20 2020-06-02 四川大学华西医院 Tapbp自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
CN111471635B (zh) * 2020-04-13 2022-02-15 江南大学 一种提高枯草芽孢杆菌核酸含量的方法
EP4182297A1 (en) 2020-07-16 2023-05-24 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
KR20230053998A (ko) 2021-10-15 2023-04-24 (주)지노믹트리 mRNA 발현을 위한 유전자 구조체
WO2024097894A1 (en) * 2022-11-04 2024-05-10 RNAimmune, Inc. Compositions and methods of ribonucleic acid vaccines encoding nye-so-1
CN115998851A (zh) * 2022-12-28 2023-04-25 四川康德赛医疗科技有限公司 一种个体化mRNA组合物、载体、mRNA疫苗及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
ATE289630T1 (de) 1999-09-09 2005-03-15 Curevac Gmbh Transfer von mrnas unter verwendung von polykationischen verbindungen
JP2004518637A (ja) 2000-11-03 2004-06-24 ワシントン・ユニバーシティ 細胞保護活性を有する修飾されたヒドロキシ置換芳香族構造体
EP1800697B1 (de) * 2001-06-05 2010-04-14 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
US7955845B2 (en) * 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
WO2005005615A2 (en) 2003-07-08 2005-01-20 Fox Chase Cancer Center Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004042546A1 (de) * 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
RU2345788C2 (ru) * 2005-09-02 2009-02-10 ООО "Научно-практический центр медико-биологических проблем "ГОРМЕЗИС" Способ лазерной вакцинации больных с метастатическими формами рака
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids

Also Published As

Publication number Publication date
CA2696768A1 (en) 2009-04-16
US20160346370A1 (en) 2016-12-01
WO2009046974A3 (en) 2009-06-18
HUE037295T2 (hu) 2018-08-28
AU2008309930A1 (en) 2009-04-16
BRPI0818318B8 (pt) 2021-05-25
SI2197481T1 (en) 2018-07-31
WO2009046974A2 (en) 2009-04-16
US20130202645A1 (en) 2013-08-08
RU2526510C2 (ru) 2014-08-20
CA2696768C (en) 2019-03-26
PT2197481T (pt) 2018-05-10
JP5139529B2 (ja) 2013-02-06
EP3375454B1 (en) 2021-04-14
CN101820899B (zh) 2014-03-12
AU2008309930B2 (en) 2013-02-21
ES2668926T3 (es) 2018-05-23
EP3375454A1 (en) 2018-09-19
BRPI0818318B1 (pt) 2020-10-13
NO2197481T3 (lt) 2018-07-14
US20100291156A1 (en) 2010-11-18
EP2197481B1 (en) 2018-02-14
RU2010118024A (ru) 2011-11-20
US20180256694A1 (en) 2018-09-13
JP2015110613A (ja) 2015-06-18
JP2010540672A (ja) 2010-12-24
CY1120168T1 (el) 2018-12-12
MX2010003766A (es) 2010-04-30
WO2009046738A1 (en) 2009-04-16
US20220096616A1 (en) 2022-03-31
US20160317636A1 (en) 2016-11-03
JP6031131B2 (ja) 2016-11-24
DK2197481T3 (en) 2018-05-22
CN101820899A (zh) 2010-09-01
EP2197481A2 (en) 2010-06-23
US9352028B2 (en) 2016-05-31
JP6012423B2 (ja) 2016-10-25
HRP20180698T1 (hr) 2018-06-29
JP2013067633A (ja) 2013-04-18
PL2197481T3 (pl) 2018-10-31

Similar Documents

Publication Publication Date Title
HRP20180698T1 (hr) Pripravak rnk za liječenje karcinoma pluća ne-malih stanica (nsclc)
EP1978986A4 (en) MICRO-RNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF LUNG CANCER
IL202040A0 (en) Hydroxymethyl substituted rna oligonucleotides and rna complexes
IL210026A0 (en) Serum or plasma microrna as biomarkers for non-small cell lung cancer
ZA201002427B (en) Lipid-modified double-stranded rna having potent rna interference effect
HK1140944A1 (en) Methods and compositions for treating recurrent cancer
EP1991230A4 (en) METHOD FOR THE TREATMENT OF CANCER
LT3098239T (lt) Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui
EP2129388A4 (en) RNA-TARGET COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2068618A4 (en) COMPOSITIONS AND METHODS OF DISCOVERING TUMOR GENES
GB0811413D0 (en) Gene expression signatures for lung cancers
IL208374A0 (en) Double-stranded lipid-modified rna having high rna interference effect
HRP20130642T1 (en) Methods and compositions for treating cancers
IL238394A0 (en) Cancer treatment method
IL201593A0 (en) Compositions comprising adenosine deaminase for use in treating tumors
GB0609386D0 (en) Treating drug resistant cancers
EP2144888A4 (en) METHODS OF TREATING CANCER
EP2151451A4 (en) COMPOSITION FOR PREVENTING OR TREATING PULMONARY DISEASE
EP2088862A4 (en) METHOD OF TREATING CANCER
PL2754441T3 (pl) Kompozycja do profilaktyki i leczenia niedrobnokomórkowego raka płuc, zawierająca pochodne pirazyno-triazynowe
EP2068911A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP2249825A4 (en) TREATMENT PROCEDURES AND COMPOSITIONS AGAINST LUNG CANCER, ADENOCARCINOMA AND OTHER MEDICAL DISEASE STATES
EP2049096A4 (en) METHOD FOR TREATING CELLS OF CHRONIC MYELOID LEUKEMIA
ZA201001876B (en) Treatment of lung cancer
EP2319873A4 (en) DEXTRAN TO TREAT LUNG CANCER